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Abstract  
Hepatocytes constitute the main bulk of the liver, and perform several essential functions. After 
injury, the hepatocytes have a remarkable capacity to regenerate and restore functionality.  
However, in some cases, the endogenous hepatocytes cannot replicate or restore the function, and 
liver transplantation, which is not exempt of complications, is required. Stem cells offer in theory 
the possibility of generating unlimited supply of hepatocytes in vitro due to their capacity to self-
renew and differentiate when given the right cues. Stem cells isolated from an array of tissues have 
been investigated for their capacity to differentiate into hepatocyte-like cell in vitro, and employed 
in rescue experiments in vivo. Adult stem cells have gained in attractiveness over embryonic stem 
cells for liver cell therapy due to their origin, multipotentiality, and the possibility of autologous 
transplantation. This review deals with the promise and limitations of adult stem cells in clinically 





 The liver is one of the largest organs and central metabolic hub of the human body.  The 
liver interacts with all body systems and receives blood through two distinct routes: the hepatic 
artery which brings blood from the systemic circulation, the portal vein which delivers blood 
drained from the spleen and digestive tract. Hepatocytes constitute the main bulk of the liver, and 
perform a wide range of functions such as protein synthesis (example, acute phase proteins 
synthesis), detoxification, carbohydrate and lipid metabolism, and bile production [1,2]. Another 
essential function is filtration due to the presence of small fenestrations that allow free diffusion of 
many substances between blood and hepatocyte surface [3].  The liver is prone to bacterial and viral 
infection, and shows tropism for circulating cancer cells, like for instance, colorectal cancer cells 
[4-6]. The liver is thus under continuous assault from various internal and external factors, which 
may alter organ function. The hepatocytes have a remarkable capacity to regenerate after injury and 
restore functionality.  However, when the inherent regenerative capacity of hepatocytes is impaired, 
liver transplantation becomes the only efficient treatment. This procedure, however, is highly 
invasive, is limited by the scarcity of donors, and is not exempt of complications. Following 
transplantation, the outcome of the patient may change on the basis of hypotension, hypoxia, 
ischaemia and hepatotoxic drugs, surgical-related aspects (intra- or postoperative hemorrhage, 
vascular or biliary complications, infections), problems posed by prolonged use of 
immunosuppressive drugs (infections, toxicity and possible neoplastic risks) or rejection [7].  
 Transplantation of hepatocytes is an attractive alternative. The first hepatocyte infusion was 
carried out as early as 1976 in the Gunn rat model which closely mimics the pathological 
manifestations in Crigler-Najjar syndrome type I patients [8,9].  Following modeling of hepatocyte 
transplantation in several animal models, the first preclinical study was performed in 1992 in non-
human primates to evaluate the safety and efficacy of infusing adult hepatocytes in the portal vein 
[10,11].  Thereafter, human clinical hepatocyte transplant has been carried out in several liver 
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diseases, mostly as therapy for innate metabolic failures or post-resectional liver failure (as a 
definitive treatment) in an effort to restore functionality [8,12].  More than 30 human cases 
receiving hepatocyte transplantation for metabolic diseases have been reported hitherto [13]. 
Human hepatocyte treatment for fulminant or chronic liver failure with acute decompensation (as a 
bridge to liver transplantation) has extended the life expectancy of patients for years [8,9,14]. 
Hepatocytes have been isolated from donated human livers considered unsuitable for organ 
transplantation. Not always good quality hepatocytes are obtained from these livers (due to long 
cold ischemic times or presence of steatosis) and, when cultured in vitro in different conditions 
(oxygenated co-cultures or microfabricated culture chips, for instance), these cells lose their 
metabolic functions after some time [9,15,16]. Recently, a long-term culture and expansion method 
of primary human hepatocytes has been described [17].  Primary human hepatocytes were 
transduced with human papilloma virus genes E6 and E7 which induce the expression of the 
oncostatin M (OSM) receptor, gp130. Thus, treatment of the cells with OSM promoted 
proliferation, and hepatocytes could be expanded for up to 40 population doublings, producing bulk 
quantity of cells in vitro. Removal of OSM enhanced the differentiation of the hepatocytes into cells 
with transcriptional, metabolic and toxicity profiles resembling those of primary hepatocytes [17].  
This is a major leap forward in the quest of finding conditions to expand primary human 
hepatocytes which maintain the capacity to undergo maturation in vitro. At the moment, this is the 
cell therapy with the best evidence of engraftment and generation of functional liver parenchyma 
compared to hepatocytes derived from other sources (described below) [13]. Still, much work needs 
to be done to obtain cell therapy-quality hepatocytes, produced under Good Manufacturing Practice 
(GMP) conditions, for liver transplant in humans.  There are, however, problems with long-term 
survival of hepatocytes.  And importantly, despite the fact that no HLA matching is required for 
hepatocyte transplant in the liver, hence allowing the use of ample donor-derived stem cells for cell 
therapy, immunosuppression is still required [9,18].   Thus, the potential advantages of using 
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hepatocyte infusions must be carefully evaluated against any possible side effects resulting from the 
use of immunosuppressive drugs, sepsis, embolization of cells into the lungs, for example [19]. 
 Another promising advance in the field of liver cell therapy has been made with the 
discovery of stem cells and their potentiality.  Stem cells offer, in theory, the possibility of 
generating unlimited supply of hepatocytes due to their capacity to self-renew and differentiate 
when given the right cues. The perfect stem cell-derived hepatocyte would be one which changes 
the trajectory of the liver disease and definitively restores functionality. Hepatocyte-like cells 
fulfilling, at least partially, these criteria have been obtained from both pluripotent embryonic stem 
(ES) cells and adult stem cells. The clinical application of ES cells, however, has been hampered by 
ethical concerns raised over the embryo use, and the problems of immune incompatibility between 
donors and recipients. Another major concern is the risk of tumor formation (teratomas) arising 
from ES cell injection. It has been shown that teratomas form in vivo not only from undifferentiated 
human ES cells, but also from human ES cells differentiated in vitro for long periods of time [20].  
Adult stem cells, on the other hand, despite their lower engraftment and repopulation efficiency 
compared to mature hepatocytes, have gained in attractiveness for liver cell therapy due to their 
multipotentiality, ability to differentiate into hepatocyte-like cells and, especially, for their use in an 
autologous way. This review deals with the promise and limitations of adult stem cells in restoring 
liver functionality. 
Methodology 
A MEDLINE search of all studies published in English (last performed on 15th June 2016) was 
conducted. Articles on the use of hepatocytes and stem cell-derived hepatocytes liver diseases were 
identified and selected using the terms "Liver transplantation AND hepatocytes AND stem cells". 
Stem cells differentiated into hepatocytes in vitro 
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 Hepatocytes are the main cell type in the liver accounting for 70% of the mass of the adult 
organ. Hepatocytes, along with biliary epithelial cells or cholangiocytes, are derived from the 
embryonic endoderm that emerges at embryonic day (E) 7.5 in mouse, and in the third week of 
human gestation [21]. The activity of two important cytokines, fibroblast growth factor (FGF) 
secreted by the developing heart, and bone morphogenetic protein (BMP) arriving from the septum 
transversum mesenchyme orchestrates the endoderm cells to adopt a hepatic fate [22]. The liver-
committed foregut endoderm cells then express transcription factors Hex and HNF4α, and the liver-
specific genes α-fetoprotein (AFP), and albumin. These cells migrate as cords into the surrounding 
septum transversum mesenchyme, and become the common progenitor cells (hepatoblasts) which 
give rise to both hepatocytes and cholangiocytes during liver development [22]. Factors employed 
for directing hepatocyte specification and maturation to induce hepatic differentiation of stem cells 
and in vitro differentiation protocols have emerged from the knowledge acquired on fetal liver 
development in vivo. Several types of adult stem cells have been differentiated in vitro into 
functional hepatocytes, and employed in preclinical studies as well as in clinical settings (Table 1). 
Some examples are described below. 
Hematopoietic stem cells 
Hematopoietic stem cells (HSCs) and hepatocytes are entwined since early embryonic development. 
The mid-gestation fetal liver is the major transitional site for mammalian hematopoiesis [21].  HSCs 
secrete several cytokines and growth factors that promote hepatocyte maturation. HSCs then 
migrate to the fetal bone-marrow, and switch from liver to bone marrow hematopoiesis occurs at 
around E16 in mice and after 70 days' gestation in humans [23,24].   The finding that the 
multipotent HSCs can participate in liver repair in adult life is therefore not such a surprise. HSCs 







in rodents and CD34 or CD133 in humans [25].  It has been shown that adult bone 
marrow stem cells such as HSCs and mesenchymal stem cells (MSCs, discussed below) are a 
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potential source of hepatic progenitor cells, termed oval cells (described below), in rodents  and are 
capable of restoring liver functions, for example in the lethally irradiated tyrosinemic FAH-/- mice, 
or following carbon tetrachloride (CCl4) induced liver fibrosis [23,26]. There are also several 
human clinical studies reporting the improvement in liver function, for example, following HSC 
transplant in liver diseases or in the setting of patients needing liver regeneration before hepatic 
resection of metastases [27-29]. The small number of cases reported, lack of defined primary end-
point as well as absence of controls render these results difficult to interpret and evaluate [27]. Furst 
et al. elegantly showed how the infusion of autologous CD133
+
 cells into the non-occluded portal 
vein following portal venous embolization with chemotherapy caused an extensive increase in the 
residual liver lobe size [29]. This increase in liver volume was significantly higher in the CD133-
treated group compared to controls thus permitting earlier surgery for resection of hepatic 
metastases. In a recent study, Schmelzle et al. showed that a subset of murine and human HSCs 
express high levels of CD39 which directs the chemotaxis and recruitment of these CD39
high
 HSCs 
from bone marrow to liver [30]. The CD39-positive HSCs significantly increased in the bone 
marrow after 70% hepatectomy in mice and promoted liver regeneration.  In the clinical setting, 
mobilization of human HSCs was observed 2 days after liver hepatectomy and was associated with 
the extent of liver resection as well as growth and functionality after hepatic resection. However, 
the mechanisms by which extrahepatic stem and progenitor cells participate in liver regeneration 
still need elucidation.  
Mesenchymal stem cells 
 MSCs, due to their multipotency, immunoregulatory/ immunosuppressive and migratory 
properties, and quasi-unlimited availability, have extensively been investigated as potential 
therapeutic options for the treatment of several degenerative diseases [31]. MSCs are derived from 
adult tissues and are considered safer in terms of tumorigenicity with respect to pluripotent stem 
cells (described below) [32]. These MSCs have been obtained from several tissues including bone 
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marrow, cord blood, amniotic fluid, adipose tissue, and most recently, from the liver [33-38]. In 
particular, there are several advantages in using adipose tissue-derived MSCs, or ASCs, for 
hepatocyte derivation:  their abundance and easy accessibility from minimally invasive procedures 
like liposuction surgery, and their higher yield of stem cells upon isolation with respect to other 
tissues [39,40]. This is a crucial point as at least one million/kg body weight of MSCs are required 
for transplantation each time [41]. Meticulously performed studies have provided the evidence that 
cells with functional characteristics of hepatocytes can be obtained from multiple tissue-derived 
MSCs in vitro. For example, when MSCs were treated with HGF, nicotinamide, and 
dexamethasone, these cells exhibited features that closely resembled human adult hepatocytes, and 
expressed hepatic markers such as albumin and AFP [42].  MSCs act at several levels in tissue 
restoration after injury. These cells provide immunomodulatory , anti-inflammatory , antifibrotic, 
anti-apoptotic and pro-proliferative features [43,44]. Several clinical studies using autologous 
MSCs, sometimes in the presence of cell-maintained biomaterials, have been performed in various 
fields (Table 1). For instance, Koh et al. have shown that the injection of ASCs and platelet-rich 
plasma into 18 patients with osteoarthritis or degenerative cartilage effectively reduced pain and 
improved knee function in patients undergoing treatment for knee osteoarthritis [45]. However, it is 
their in vivo propensity to stimulate resident cells and matrix remodeling, through expression of 
trophic factors (growth factors and anti-fibrotic molecules such as HGF and cytokines) to promote 
the differentiation of native progenitor cells as well as the recovery of injured cells, that makes 
MSCs optimal candidates for liver repair [28,41,46]. For example, allogenic bone marrow-derived 
MSCs transplantation has been performed in patients with primary biliary cirrhosis, and the 
outcome was the improvement in liver function [47].  Other clinical trials investigating the effect of 
bone marrow-derived stem cells in patients with liver disease have been performed and have 
established the safety and feasibility of stem cell therapy in patients with liver diseases (extensively 
reviewed in [44]). On the other hand, some studies have pointed out to the possibility that MSCs , 
for instance, those derived from bone marrow, may contribute to the hepatic stellate cell populations 
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and myofibroblast pool, and thus, promote the fibrotic process within the liver [48,49]. Excessive 
extracellular matrix deposition may occur overcoming the MSC-induced cytoprotective effect 
taking place during the initial repair process [41]. Thus, more clinical studies are needed to ensure 
that MSCs, especially the ones derived from the bone-marrow, can be safely employed to generate 
new hepatocytes to replace damaged ones without leading to fibrosis.  
Adult pluripotent stem cells  
 The pluripotent stem cells par excellence are the ES cells but due to ethical and 
immunological concerns, their use in the clinic has been forbidden in most countries. The scientific 
breakthrough of the group of Yamanaka has offered the possibility of obtaining adult pluripotent 
alternatives [50]. Induced pluripotent stem (iPS) cell, generated by reprogramming of somatic cells, 
are very attractive for regenerative therapy for the following reasons. These adult cells can be 
expanded for long period in culture without karyotype change; they can be frozen and thawed 
without loss in viability as may happen for other types of adult stem cells; and most importantly, 
they can give rise to derivatives of the three germ layers upon differentiation induction without the 
concern for immune rejection for potential patient-tailored therapy [50,51]. Functional hepatocytes 
have been derived in vitro from human iPS cells, both of human and mouse origin, by several 
groups [52-54].  HNF4, albumin, cytokeratin 18 (CK-18), glucose 6-phosphate (G-6P), cytochrome 
P450 3A4 (CYP3A4), and cytochrome P450 7A1 (CYP7A1) were expressed by the iPS cell-
derived hepatocytes [54]. Moreover, in functional assays, these cells showed accumulation of 
glycogen, and demonstrated uptake and excretion of indocyanine green, as well as secretion of 
albumin into the medium [53]. These iPS cell-derived hepatocytes rescued lethal fulminant hepatic 
failure in mice [53,54]. Thus, patient-specific iPS cell-derived hepatocytes can be obtained for 
promoting liver regeneration in vivo or for therapeutic compound testing or studying disease 
mechanisms in vitro.  However, one of the most important concerns about use of iPS cells 
compared to that of adult stem cells is the possibility of developing some tumoral tissue [55]. Thus, 
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it is important to ensure that full differentiation of ES-like cells has occurred before proceeding to 
transplantation in humans.  Efforts are now being made to improve the mechanism and method for 
generating tumor-free iPS cells, like employing the suicide-gene strategy or using regulatory 
miRNAs in iPS cell-based therapy [55,56].  Despite all hurdles and controversies, clinical trials in 
treatment of spinal cord injury, macular degeneration of retina, type 1 diabetes and heart failure are 
under way [57].  
 Pluripotent stem cells derived from spermatogonial stem cells, termed herein as germline 
cell-derived pluripotent stem cells (GPSCs), are also adult stem cells with the major features of ES 
cells. The difference with iPS cells is that mouse GPSCs are obtained spontaneously from long-term 
cultures of spermatogonial stem cells and do not necessitate the genetic reprogramming by forcing 
gene expression for their derivation. GPSCs are thus of particular interest for tissue regeneration 
[58]. The first clue that GPSCs can be directed to differentiate into hepatocyte-like cells came from 
the study of Guan et al. [59]. GPSCs were cultured as "hanging drops" for five days, and plated 
thereafter. Hepatocyte-like cells were observed in the embryoid bodies, and gene expression 
analyses revealed that the early (AFP) and the late (CK-18) markers of hepatocyte differentiation 
were expressed. Successively, GPSCs were induced, using two different hepatic differentiation 
approaches, to differentiate in hepatocytes in vitro and were compared to other pluripotent stem 
cells [60]. GPSC-derived hepatocytes showed prominent expression of AFP, albumin, CK-18, and 
c/ebp-α and acquired a polygonal-shaped hepatic morphology. These cells also secreted albumin in 
culture supernatant. We confirmed these results and further showed that GPSC-derived hepatocytes 
were metabolically active as shown by albumin and haptoglobin secretion in the culture 
supernatant, urea synthesis, glycogen storage, and indocyanine green uptake [51]. Infection of 
GPSC-derived embryoid bodies with lentivirus expressing GFP under hepatocyte-specific enhanced 
transthyretin promoter revealed that 82.68% of cells were hepatocytes in long-term culture (on Day 
35 of differentiation) [51,61]. An OP9 co-culture system was also shown to efficiently generate 
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functional and mature hepatocytes cells from GPSCs [62]. Recently, our group demonstrated that 
the hepatoblast marker, Liv2, -sorted GPSC-derived hepatocytes were functional in vitro, and could 
engraft and colonize Hfe-null mice livers following monocrotaline treatment and partial 
hepatectomy [63]. These studies showed that GPSC-derived hepatocytes could undergo long lasting 
engraftment in the mouse liver and are promising for liver regeneration. The starting cell type, 
spermatogonial stem cells, also show multipotent characteristics when given the right differentiation 
cues. To this regard, it was demonstrated that both mouse spermatogonial stem cells can directly 
transdifferentiate in vitro into cells with morphological, phenotypic and functional attributes of 
mature hepatocyte-like cells [64]. More recently, mature and functional hepatocytes have been also 
obtained by direct differentiation from freshly isolated human spermatogonial stem cells [65]. Thus, 
it may be possible to rapidly and directly differentiate adult spermatogonial stem cells into mature 
and functional hepatocyte-like cells, without waiting for the pluripotency acquisition process. The 
field is now open to finding the right culture conditions for the long-term culture of human 
spermatogonial stem cells (to derive human GPSCs) and to assess the clinical potentiality of both 
spermatogonial stem cells and GPSCs.   
Resident stem cells 
 Mature hepatocytes are usually quiescent and show minimal turnover [66]. However, 
following injury induced by partial hepatectomy or chemical insult, hepatocytes exit the G0 phase 
and undergo cell proliferation to compensate for cell loss [42]. Resident stem cells are also thought 
to be involved in the liver regeneration process. Oval cells, defined as a population of small 
proliferating cells with oval-shaped nuclei in rodents, surge within the liver following injury [67]. 
Oval cells are bipotent cells that are capable of generating both hepatocytes and bile duct cells [68]. 
Some studies have reported the identification of oval cell equivalent in human in the so-called 
"ductular reaction" [68].  Bipotential progenitor epithelial cells resembling rodent oval cells, 
morhologically and immunohistochemically, have been traced in the regenerating areas in patients 
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with chronic liver injury in subacute hepatic failure [69,70]. Recently, Huch et al. have reported the 
long-term culture of adult bile duct-derived bipotent stem cells isolated from human liver biopsies 
[71]. Interestingly, these cells could be induced to differentiate into functional hepatocyte cells in 
organoids in vitro and upon transplantation in vivo in mice.  These data suggest that the human 
counterpart of oval cells exists and may participate in liver regeneration. Whether these cells 
originate in the liver itself or in extrahepatic sites such as the bone-marrow still remains a matter of 
doubt [72]. Lineage tracing experiments may help in this direction. Some studies indicate that the 
activation of progenitor cells (oval cells in rodents) may lead to the histogenesis of hepatocellular 
carcinoma or in the development of liver fibrosis [73,74]. More studies are thus needed to clarify 
the mechanisms that in one instance leads to the hepatic differentiation of oval cells in normal liver, 
and on the other hand, promotes their carcinogenicity under pathological conditions.    
 A population of human liver stem cells (HLSCs) has also been isolated from surgical 
specimens of patients undergoing hepatectomies or from cryopreserved normal hepatocytes [68,75]. 
These cells express mesenchymal stem cell markers, and can be induced to differentiate into mature 
hepatocytes when cultured in the presence of HGF and FGF4 in rotary cell culture system in vitro.  
In vivo, HLSCs contributed to liver regeneration when injected in SCID mice with N-acetyl-p-
aminophen-induced acute liver injury and improved survival of mice with fulminant liver failure 
[68,75].  Thus, these preclinical studies are a prelude to assessing the clinical use of HLSCs. 
Regarding the use of human adult liver stem cells in treating inborn errors of liver metabolism, 
patients have been included in phase I/II studies, including Crigler-Najjar and urea cycle 
disorders[76].  
In vitro systems for obtaining functional hepatocytes from stem cells  
 Stem cells-derived hepatocytes cultured on different extracellular matrix components in 
monolayers do not undergo full maturation in vitro.  Using 3D bioreactors and rotating microgravity 
conditions, some studies have demonstrated that hepatocyte viability and function can be improved 
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and maintained for several weeks [68,77].  However, there are contrasting data regarding the effect 
of microgravity on differentiation. Lately, it has been reported that microgravity reduces the 
differentiation and regenerative properties of stem cells [78]. Thus, other settings have to be devised 
to promote maturation of stem cells into functional hepatocytes in vitro. It is known that 
hepatocytes need heterotrophic cell interactions with non-parenchymal cells which regulate 
differentiation and proliferation in a 3D microenviroment in vivo [79]. Importantly, stem cell-
derived hepatocytes need the optimal microenvironment when transplanted in the case of end-stage 
chronic liver disease, for instance, in which the liver architecture is extensively destroyed and the 
liver parenchyma is replaced by fibrosis with reduced blood supply.   Generation of acellular liver 
scaffolds from rat or human liver for repopulating these with stem-cell derived hepatocytes is a 
great step forward in mimicking the in vivo system (Figure 1).  For instance, rat liver scaffolds were 
recellularized with HLSCs and maintained for 21 days in different culture conditions to evaluate 
hepatocyte differentiation [80]. The rat extracellular matrix enhanced HLSC differentiation into 
functional and metabolically hepatocytes, and promoted the formation of both epithelial-like and 
endothelial-like cells [80].  Human segmental lobes or whole liver have been also decellularized 
and characterized [81]. The scaffold was repopulated with different human hepatic cell lines for up 
to 21 days, and allowed efficient engraftment, homing to correct location, and proliferation of these 
cells. The human liver scaffold also showed biocompatibility when xenotransplanted into immune-
competent mice [81].  This is a major progress in devising bioartificial livers for repopulation with 
stem cell-derived hepatocytes for the treatment of liver diseases.    
Modeling human diseases for assessing stem cell-derived hepatocyte function 
 Stem cell-derived hepatocytes have been transplanted mainly in rodents to test their 
functionality in vivo. To counteract the rejection of human cells by the rodent immune system, 
immunodeficient mice have been employed for the transplantation of stem cell-derived hepatocytes. 
But often the human cells do not proliferate in normal livers. Thus, several animal models, in which 
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proliferation of endogenous hepatocytes is severely compromised, either by genetic causes or by 
accumulation of toxic products,  have been generated. For instance,  fumarylacetoacetate hydrolase 
(FAH)-deficient mice and urokinase (alb-PA) transgenic mice with liver regeneration defects, have 
been transferred into an immuno-compromised background to receive human cells [79]. 
Transplanted stem cell-derived hepatocytes thus have selective growth advantage over endogenous 
hepatocytes, and homing, engraftment, and proliferation, as well as functionality can be assessed.   
Mice with inherited liver metabolic diseases caused by genetic mutations in key proteins, for 
example, Crigler-Najjar in which the Ugt1A1 gene is mutated, have been generated, and crossing 
these mice with immuno-compromised mice will help in assessing whether human stem cell-
derived hepatocytes can rescue the phenotype [82]. These mice have normal liver, and a way to 
make exogenous hepatocytes home and proliferate has to be found. The engrafted cells will thus 
restore the activity of the enzyme UDP- glucuronosyltransferase A1. Thus, apart from cell therapy, 
stem cells also serve as a platform for gene therapy. In humans, such an approach can be envisaged 
in personalized gene/stem cell therapy combination following genome editing.   
 Several routes of cell delivery to the liver have been exploited.   The most convenient mode 
of stem cell-derived hepatocyte transplantation is the intravenous route [83]. This delivery route 
takes the injected cells to the lungs and successively to the liver. Liver injury and release of cell 
attracting chemokines are required for homing of injected cells.  The spleen is also a good site for 
hepatocyte injection. The hepatocytes infused into the spleen undergo blood flow–mediated 
translocation to the hepatic sinusoids [84]. However, a large number of cells remain trapped in the 
spleen. Other routes of infusion include hepatic artery and portal vein [85]. Intraparenchymal 
hepatocyte transplantation is another way of delivering cells to the liver [63]. Directed injection 
results in grafted cells that remain localized to the liver. Most recently, hepatocyte sheets were 
attached onto the surface of mice livers following injury and showed high potential for cell 
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engraftment of this sheet transplantation procedure [86]. Thus, the therapeutic values of stem cell-
derived hepatocytes can be assessed in vivo using these different routes of cell delivery to liver.  
Stem cell secretome in mediating beneficial effect on liver 
 Liver regeneration occurs, not only through transplanted stem cell proliferation and 
maturation, but also by the paracrine factors released by these cells. It was shown that 
microvesicles, which are shedded vesicles ranging from 100nm to 1µm in size, can horizontally 
transfer genetic information to target cells [87]. In vivo administration of microvesicles derived 
from HLSCs promoted in vivo liver regeneration in 70% hepatectomised rats [88]. The HLSC-
derived microvesicles contain ribonucleoproteins involved in RNA biogenesis, microRNAs 
associated with multiple cell functions like transcription, translation and proliferation, as well as 
proteins [89]. Microvesicles also have other interesting properties. Recently, Fonsato et al., 
demonstrated that HLSC-derived microvesicles could block the proliferation and survival of 
hepatocellular carcinoma cells in vitro, and induced the regression of ectopic tumors developed in 
SCID mice [90]. MicroRNAs contained in the microvesicles mediated the anti-tumor activity. 
Interestingly, cells can be genetically engineered to produce microvesicles carrying suicide 
mRNAs/proteins to target tumor cells [91]. Mesenchymal stem cell-derived extracellular vesicles 
have also been beneficial in several acute and chronic liver disease models (reviewed in [92]). 
Recently, comparison of adult-derived human liver stem/progenitor cells (parenchymal) to hepatic 
stellate cells (non-parenchymal) revealed that the former secreted cytokines with therapeutic and 
immuno-modulatory properties with respect to hepatic stellate cells [46].  Thus, stem cells can be 
beneficial for liver therapy not only physically, but also by effectively delivering therapeutic 
mRNA/proteins for repair and tumor regression.  
The still unmet challenges  
 Several aspects of liver cell/gene therapy need further investigations before stem cells can be 
efficiently used in the clinic. In animal models employed hitherto, it has been possible to block 
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endogenous hepatocyte proliferation with alkaloids such as monocrotaline, hence favoring the 
replication of transplanted stem cells. In patients, however, a similar treatment cannot be applied. 
Thus, strategies to harness growth advantages of stem cells in human liver which present a normal 
phenotype, like in the case of Crigler-Najjar syndrome, should be elaborated. Future studies will 
determine whether co-transplantation of stem-cell derived hepatoblasts and "helper" liver-derived 
stromal cells will engraft and gradually replace morphologically (but not metabolically) normal 
hepatocytes as was described in the rat [13]. However, fibrosis, which may occur as a side effect of 
such a procedure, should be taken into consideration. Standardization and protocols should be 
implemented for isolation, purification, culture conditions and passages, expansion, and hepatocyte-
specific induction following Good Manufacturing Practice guidelines [93].  To which extent a stem 
cell should be differentiated in vitro to be considered fit for transplantation should be also 
standardized. To this regard, expression of markers of hepatocyte differentiation should be closely 
followed to assess the differentiation stage before cell injection.  And whether hepatoblasts or fully 
mature hepatocytes should be injected in the diseased liver also remains a matter of concern, 
especially because some studies have shown that fetal hepatocytes proliferate, engraft and 
repopulate livers better than more mature ones [94]. But then, when considering iPS-derived 
hepatocytes, for example, the more differentiated the better it is? All these questions are still 
without an answer. The risk assessments for the liver transplantation of each stem cell type should 
be evaluated in clinical studies due to the fact that the isolation procedures as well as culture 
conditions can alter clinical efficacy and safety. 
 Future research should also address the issue of time. The time taken to isolate, expand and 
prime patient-specific stem cells into hepatocytes should be greatly reduced, so that autologous 
transplantation can be carried out in a timely manner, especially for acute hepatic diseases. Whether 
autologous stem cell therapy will be applicable in case of human fulminant hepatic failure, in which 
rapid deterioration of the liver function occurs and immediate cure is required, remains a matter of 
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concern. Moreover, following transplantation, stem cell-derived hepatocytes encounter a complex 
and hostile environment in which local hypoxia, oxidative stress, and inflammation may induce cell 
death. Insufficient retention and survival of transplanted cells may drastically dampen their 
therapeutic effects. Thus, tissue engineering approaches (for example, tissue scaffolds) should be 
ameliorated, and the addition of adjuncts that increase the proliferation as well as differentiation of 
stem cells into not only hepatocytes, but also all the other cell types making up the liver such as 
sinusoid endothelial, Kupffer, stellate and biliary epithelial cells may help in this regard [40].   
 An important issue is the fate of the stem cell-derived hepatocytes once injected in the 
patients through different routes mentioned above. Do these cells migrate to the liver? Do they 
complete their differentiation or are eliminated after some permanence in the liver? Another still 
unanswered question is whether the bone marrow-injected stem cells infused into patients really 
differentiate into hepatocytes or fuse with pre-existing ones or remain unaltered and release 
paracrine factors such as growth factors, angiogenic factors, cytokines, microvesicles, among 
others, to enhance regeneration through the stimulation of resident parenchymal or progenitor cells. 
Moreover, while in preclinical models, it is possible to assess engraftment and colonization 
efficiency of transplanted cells by an array of cell tracking methods (fluorescent dyes, magnetic 
resonance imaging) available, it is often technically difficult to perform on the long-term in patients 
in the clinical setting.   Couto et al. employed 99mTc-SnCl2 specific for mononuclear cell labeling 
to gain knowledge on the biodistribution of peripherally-infused bone marrow mononuclear cells in 
cirrhotic patients [95]. Interestingly, the authors found that approximately 41% and 32% of the 
radioactivity, as revealed by whole body scintigraphy, was retained in the liver 3 and 24 h after 
injection, respectively. Cell tracking, in this case, helped in assessing the correct homing of the 
injected cells to the liver at early time points, but could not be used to assess the colonization 
efficiency months after cell injection. Only one infusion of cells is temporarily beneficial. Repeated 
injections are probably needed to permanently reverse the damage [95]. For instance, in a Phase II 
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study, patients with complex perianal fistulas were randomly assigned to intralesional treatment 
with fibrin glue or fibrin glue plus 20 million ASCs [96].  In the absence of healing, a second dose 
of fibrin glue and 40 million ASCs were administered to the patients, and this enhanced the  
probability of healing by more than four times in patients treated with ASCs plus fibrin glue than in 
patients treated with fibrin glue alone. A retrospective study performed on these patients showed the 
long-term safety of the treatment despite the fact that a low proportion of patients treated with stem 
cells with closure after the procedure had no recurrence after 3 years' follow up [97].   
 Several studies have shown the long-term rescue of liver diseases using primary hepatocyte 
transplantation [98,99]. That hepatocytes derived from all different adult stem cell types can 
efficiently engraft and restore liver function on the long-term still need detailed investigations 
[100]. Large randomized controlled clinical trials are required to get robust data on the benefit of 
adult stem cell transplantation in liver diseases  and to tailor treatment to individual patients, thus 
reducing the risk of rejection [44]. Despite the fact that several studies using stem cells in the 
treatment of liver diseases have shown beneficial effects, the underlying mechanisms responsible 
for their therapeutic effects are still unknown. Moreover, the percentage of liver colonization is still 
very low in spite of arduous efforts to ameliorate cell engraftment.  The best application route 
should be investigated for each adult stem cell type used in order to maximize engraftment. 
Transplanted stem cell-derived hepatocytes secrete factors that contribute to liver repair and 
regeneration, but what recovery processes are regulated by these soluble factors remain 
undetermined. 
 The bone marrow contributes functionally and significantly to liver fibrosis and is a 
potential therapeutic target in liver fibrosis [49]. However, there are controversies on this subject 
that still have to be dealt with. MSCs from bone marrow have also been reported to inhibit hepatic 
stellate cell activation or induce their apoptosis, particularly via paracrine mechanisms, and 
therefore, may be considered in the treatment of liver fibrosis [101]. Clinical studies on bone 
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marrow cell therapy for liver regeneration and repair should thus proceed cautiously while 
evaluating the risk of hepatic fibrosis development [102]. 
 In case of liver cancer, stem cells may create an immunosuppressive environment by 
providing anti-aging, anti-oxidative effects, for example by reducing reactive oxygen species, and 
hence favor the escape of tumor cells and promote metastasis formation [103].  When performing 
therapy with stem cells, one should not lose sight of the possible implication of these cells in 
carcinogenesis (reviewed in [104]). In the liver, several cell types (hepatocytes, cholangiocytes, 
progenitor cells) live long enough to  be the cell of origin of cancer [105]. In fact, the presence of 
CK7 and CK19-positive progenitor cells has been found in a substantial number of hepatocellular 
carcinoma cases [106]. Hepatocellular carcinoma may also originate from the transdifferentiation of 
bone marrow cells as also happens in other sites of the digestive tract [107,108]. These results 
suggest that there may be more than one type of carcinogen target cell in the liver.  
 
Conclusions 
Adult stem cells have been isolated from diverse body tissues and their capacity to differentiate into 
hepatocyte-like cells in vitro and restore liver functions in vivo has been investigated extensively, as 
depicted in Figure 2. Now, the major goal is to translate the knowledge gained on animal models 
into clinic which is awaiting the "perfect" stem cell(s) to reduce death caused by acute and chronic 
liver diseases, often not curable by pharmacological approach. Hepatocyte infusion and stem cell-
derived hepatocyte transplantation performed in humans are till now only bridging therapies to 
orthotopic liver transplantation, and much improvement is required to fulfill the main aim of cell 
transplantation, that of partially replacing the missing function without having to undergo liver 
transplantation [13]. Bridging therapy is very important in the case of pediatric liver diseases, 
especially because it helps in extending the lifespan of children until liver transplantation can be 
safely performed. More preclinical studies regarding the long-term engraftment and hepatocyte 
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repopulation are necessary, and more clinical data as well as controlled clinical experimentation are 
required not only with regard to dosage, application route and therapeutic mechanisms involved but 
also on the potential bidirectional role of the stem cells in carcinogenesis before firm conclusions 
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